| answer text |
<p>The United Kingdom has a long-established and globally-recognised track record
of assessing the price of new, innovative medicines by their clinical benefit and
value, rather than by their development costs or international reference prices. It
is crucial that patients have access to the most effective and innovative medicines
at a price that represents value to the National Health Service. The Government fully
supports the approach the National Institute for Health and Care Excellence and NHS
England are adopting in the ongoing negotiations with Vertex Pharmaceuticals on access
to their portfolio of cystic fibrosis medicines.</p><p> </p><p>The UK will engage
constructively with the talks at the World Health Assembly to achieve the best outcome
for people here and globally, including in low and middle income countries. Pricing
arrangements are the responsibility of Member States and are highly context specific,
but the Department supports information sharing and mutual learning initiatives, where
appropriate, in seeking to improve value for money for country procurement budgets.</p>
|
|
